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ABSTRACT
Primary immune thrombocytopenia is an
autoimmune disorder of unknown cause
affecting both children and adults. The low
peripheral blood platelet count is caused by
premature platelet destruction by self-reacting
antibodies in addition to an impairment of
platelet production. The disease is
heterogeneous in its pathophysiology, clinical
features and responses to treatment. To date,
most of the treatments used have been
immune-modulating drugs and these
contribute to increased morbidity and
mortality in patients. A new class of drugs, the
thrombopoietin receptor agonists, has been
developed for use in ITP. These have gone
through randomised controlled trials in large
numbers of patients with ITP. These drugs have
high efficacy and are well tolerated. In addition,
around 30% of patients receiving these drugs
are able to stop them and maintain a safe or
normal platelet count. Older treatments such as
splenectomy are being used less than before,
largely because of the introduction of the
thrombopoietin receptor agonists. Currently
there are trials underway evaluating novel
therapies for ITP that will become available




Romiplostim; Second-line therapy; Sustained
responses; TPO receptor agonists
INTRODUCTION
Primary immune thrombocytopenia (ITP) is an
acquired autoimmune disorder affecting both
children and adults, characterised by a platelet
count below 100 9 109/l [1, 2]. Clinical
manifestations include petechiae, purpura,
bruising, and overt bleeding. Previously, ‘acute
ITP’ was used to describe a self-limited form of
disease and ‘chronic ITP’ thrombocytopenia
described the disease if is lasted for more than
6 months. In 2009 new terminology for ITP was
agreed upon based on the duration of the
disease. The new terms for ITP are: ‘newly
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diagnosed’ (from diagnosis until 3 months),
‘persistent ITP’ (3–12 months) and ‘chronic
ITP’ (ITP lasting for more than 12 months) [2].
Chronic primary ITP in adults is slightly more
common in women of childbearing age but the
sex incidence is similar in patients over 60 [2, 3].
The incidence of ITP in adults is around 4 per
100,000 people per year, with a UK prevalence
of up to 24 per 100,000 people [4–6].
Bleeding is highly variable and there is great
heterogeneity in primary ITP. Bleeding is most
commonly mucocutaneous, involving gum
bleeding, blood blisters in the mouth and
menorrhagia. Major bleeding is not common if
the platelet count is above 30 9 109/l. The most
serious form of bleeding, intracranial
haemorrhage, is rare and is most often seen in
older patients who have additional
comorbidities and in patients who fail to
respond to therapy [7]. The yearly risk of fatal
haemorrhage is around 1.6–3.9% [8]. This risk
varies with age, at 0.4% per annum in those
below the age of 40 years to 13% per annum
over patients over 60 years of age.
The aims of this review are to provide a brief
overview of ITP and its current management.
The main emphasis of the review is on the
recently introduced TPO receptor agonists
focussing on published trial data. Both
romiplostim and eltrombopag are discussed in
detail, including recently published studies that
show the unexpectedly high rate of sustained
responses to these agents following their
discontinuation.
CLINICAL FEATURES
Paediatric and adult ITPs are quite different in
terms of their underlying pathophysiology and
clinical outcomes. In children, ITP may follow a
viral infection or immunisation. In most
children the disease remits spontaneously by
6 months with little need for medical
treatment. Around 15% of children will go on
to develop chronic ITP.
In the adult form of the disease there is
usually no prodrome. Instead, the patient may
notice an increase in bruising, or petechiae. In
many cases ITP in adults is picked up by chance
when the patient has a full blood count for
other reasons, for example, preoperatively. This
is seen particularly in the elderly when nearly a
third will be diagnosed by chance.
ITP in adults is extremely heterogeneous.
Many patients have no clinical problems related
to their thrombocytopenia even at very low
platelet counts, while other patients may have
bleeding from the outset and a study of practice
in Europe over 1 year showed that 40% of
patients had no bleeding at all despite low
platelet counts and required no treatment [9].
The platelet count by itself is an unreliable
predictor of clinical outcome. Many factors
contribute towards the bleeding risk including
age, comorbidities, medication, prior bleeding
history and other factors not yet identified. In
some patients an autoantibody may bind to a
critical epitope on the platelet glycoprotein and
interfere with platelet function. Autoantibodies
reacting with glycoprotein (GP)IIb/IIIa may
affect platelet aggregation; these are the most
common autoantibodies seen in primary ITP
[10]. Antibodies against GPIb/IX may impair
platelet adhesion to the subendothelial matrix,
thereby causing severe bleeding for the level of
platelet count. Other autoantibodies including
antiphospholipid antibodies are detected in up
to 30% of patients with ITP. These may affect
platelet and vascular function. Overall,
however, despite the severity of the
thrombocytopenia, severe bleeding is not
common in ITP, in contrast with
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thrombocytopenia following chemotherapy or
bone marrow failure [11].
MANAGEMENT OF ADULT ITP
ITP in adults is a disease with low morbidity and
mortality. Most patients with ITP have few
problems related to the thrombocytopenia but
a minority may be resistant to treatment and
have a platelet count that is chronically low.
After the publication of the original American
Society of Hematology guideline in 1996 [12]
there was a tendency to treat most patients
whose platelet count was\30 9 109/l. Most of
the treatments available until fairly recently
had significant side effects for many patients.
Because of the immune suppression often used
to treat ITP, patients are at increased risk of
infection. A study of 152 consecutive adult ITP
patients published by Portielje and colleagues
showed that the treatments used contributed
significantly to an increase in morbidity and
mortality in their cohort [13]. Contrary to what
might be expected, half of the deaths observed
in the study were attributable to the treatment
used rather than haemorrhage. MacMillan
showed this to be a particular problem in
patients who had failed splenectomy and
required continuing immune suppressive
therapy [7].
Patients with ITP who have low platelet
counts bleed less than patients with aplastic
anaemia or chemotherapy-induced
thrombocytopenia at equivalent platelet
counts. For this reason, in addition to the
toxicities of the treatments used discussed
earlier, there has been a relaxation in the
platelet thresholds for treatment. The
International Consensus Report [3] suggested
not treating patients whose platelet counts were
[50 9 109/l. At this platelet count most
patients will have few symptoms or signs of
ITP. Patients whose platelet counts are lower
may also require little treatment depending on
their age, comorbidities and bleeding history.
Overall the number of patients with ITP who are
on no treatment has risen over the past decade
whilst the number of patients receiving medical
treatment has fallen.
The main aim of treatment is to achieve a
safe platelet count for each patient on a
case-by-case basis [14]. The intention is not to
normalise the platelet count. In general,
treatment is seldom required when platelets
are greater than 20 9 109/l. For patients with
platelets less than 20 9 109/l treatment may be
required but this depends on a full assessment
of the patient including lifestyle, occupation,
bleeding history, comorbidities and other
factors.
Initial first-line treatment has remained
unchanged for decades and comprises
corticosteroids [15], IVIg [16, 17] and anti-D
[18] in countries where the latter is available.
Corticosteroids are cheap, raising platelet
counts rapidly within 1–2 days in around 75%
of patients. However, long-term responses are
seen in only 25% of patients. Side effects are
extremely common and predictable. Currently
available corticosteroids include prednisone,
prednisolone, methylprednisolone and
dexamethasone. Prednisolone has been used
predominantly as first-line treatment rather
than dexamethasone but recent studies of the
latter suggest that the response rates are higher
and prolonged remission is seen more
commonly [19]. However, despite this,
prednisolone remains the first-line
corticosteroid of choice [3].
There have been several trials of IVIg in ITP
since its first use in the mid-1980s. The response
rate in ITP is similar to that of corticosteroids
but the time to response is shorter, with a
response normally seen within 24 h although
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most are transient rarely exceeding 3–4 weeks.
Toxicities include headache, renal impairment
and thrombosis.
Intravenous anti-D is effective in 80%
patients with primary ITP and is suitable for
those who are Rh(D) positive and have not
undergone splenectomy. The infusion time is
shorter than for IVIg and the donor pool from
which it is derived is much smaller than that of
IVIg. Anti-D has been shown to induce a longer
response time than IVIg [20] and may also
reduce the need for splenectomy [21].
SECOND-LINE THERAPY
If a patient fails to respond to first-line
treatment or relapses following a response
there may be a need to introduce a
second-line treatment. These treatments
include medical therapies and splenectomy.
The medical treatments used as second-line
therapy have undergone few randomised
controlled trials and a systematic review
covering nearly 700 patients showed that
complete remission rates rarely exceed 15%
and few of the individual studies have
sufficiently large numbers of truly refractory
patients to make a definitive recommendation
[22]. Most of these drugs are not licensed for ITP
and have been chosen because of their efficacy
in other autoimmune diseases or in post-solid
organ transplant immune suppression. The
recent International Consensus Report
provides a list of second-line therapies placed
in alphabetical order because there were
insufficient data to rank the treatments in
order of efficacy, apart from the
thrombopoietin receptor agonists, which have
undergone rigorous randomised trials [3].
The immunosuppressants azathioprine,
ciclosporine and mycophenolate have shown
most efficacy in adult ITP although most studies
are small. These are in general small, open
studies and response rates should be considered
with some scepticism. Azathioprine produces
complete responses in 45% of patients [23].
Ciclosporine has been shown to improve
platelet counts in one study of 80%, with 42%
patients achieving a complete response [24, 25].
Durable remissions have been reported after
ciclosporine has been stopped [25]. Side effects
include fatigue, renal insufficiency,
hypertension and neuropathy. Mycophenolate
mofetil has been shown to be of value in ITP.
This immunosuppressant is similar to
azathioprine and ciclosporine and is an
anti-proliferative agent [26]. An overall
response rate of 78% has been reported.
Interestingly, prolonged remissions of 25%
have been reported in patients on
mycophenolate [27].
Rituximab is been licensed for rheumatoid
disease and has been used for some years in ITP
with initial responses of 60% and durable
responses of 15–20%. However, there are
safety issues with rituximab including
progressive multifocal leucoencephalopathy
(PML) and hypogammaglobulinaemia in
addition to the lack of approval for its use in
ITP [28–30]. A more recent randomised placebo
controlled study using rituximab in the
second-line setting demonstrated a much less
favourable response, and although those who
achieved CR on rituximab had a more durable
response the benefits were small [31]. For these
reasons rituximab usage will probably decline
particularly with the wide availability of the
newer TPO receptor agonists. Rituximab may be
used at the standard dose (375 mg/m2) or low
dose at 100 mg weekly for 4 weeks [32].
Response to rituximab is generally seen after
1–2 weeks but in some patients a response may
be seen up to 2 months after the last infusion
[28, 30].
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Cyclophosphamide, an alkylating agent, has
been used successfully in adult ITP. It can be
given orally at 1–2 mg/kg/day for up to
4 months or it may be given IV at 0.3–1 g/m2
for between 1 and 3 doses every 2–4 weeks. The
reported response rate is 24–85% [33, 34].
Danazol is an attenuated androgen and is
given orally at 200 mg between two and four
times per day. The response rate is around 60%
[35]. Danazol may be more effective in older
females and those patients who have not
undergone splenectomy [35].
Dapsone is an anti-leprotic drug that has
been used successfully in ITP. It is usually given
at 75–100 mg/day orally. Responses may be seen
in up to 50% patients [36]. Because of its risk in
glucose-6-phosphate dehydrogenase deficiency,
at-risk males should be screened for this before
starting dapsone. It is however a very cheap
form of treatment and is widely used in the
developing world.
Splenectomy has been used as a second-line
treatment for ITP for 100 years [37]. Following
splenectomy there is an early response rate of
80% but over time relapses occur and the
long-term response rate is closer to 66%
[38–40]. Even if splenectomy fails to induce a
complete remission, many patients may still
experience a partial response to splenectomy
with a platelet count that is higher than that
before splenectomy [12, 41].
Since splenectomy is a surgical procedure
there are risks associated with this including
bleeding, thrombosis and infection.
Complication rates are highly variable
depending on a number of factors [13, 38, 39,
42, 43] and are higher in older patients [44] and
in open splenectomy compared to laparoscopic
splenectomy [39].
A number of tests for predicting the likely
response to splenectomy have been proposed
including response to corticosteroids or IVIg
[45] but these are seldom used as predictors. The
best current method for predicting response to
splenectomy is the indium-labelled platelet
survival scan [46–48]. For patients in whom
the platelet destruction is pure or
predominantly splenic the chance of a
response to splenectomy is around 90% [49].
Unfortunately this test is only available in a few
centres worldwide.
Before carrying out splenectomy patients
should be vaccinated against Streptococcus
pneumoniae, Haemophilus influenzae and
Neisseria meningitidis [3]. These vaccines may
not be effective in patients who have received
rituximab in the 6 months prior to
splenectomy. Following splenectomy patients
should be given prophylactic antibiotics such as
phenoxymethylpenicillin 250–500 mg twice
daily or the equivalent if allergic, possibly for
life, although there is no consensus on the exact
duration of the prophylaxis. In addition,
patients should keep a supply of
broad-spectrum antibiotics at home, which
they should take if infection is suspected. They
are also advised to seek immediate medical
attention [50].
With the availability of the TPO-receptor
agonists and the long-term responses these
may induce one might argue against
splenectomy being a valid second-line therapy
today. The rate of splenectomy for ITP is
falling worldwide and many patients would
benefit from deferring splenectomy until they
have tried other lines of treatment including
TPO-receptor agonist. Unpublished data from
the UK Adult ITP Registry have shown a 10%
reduction in splenectomy rates since the
publication of the International Consensus
document [3]. Even if their platelet count is
low it may be safe enough for normal
day-to-day living with no requirement for
splenectomy.
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THROMBOPOIETIN RECEPTOR
AGONISTS
TPO is the primary factor regulating platelet
production [51]. Several TRAs have been
developed that activate the TPO receptor and
increase platelet production [52–56].
Two drugs, eltrombopag and romiplostim,
are currently FDA-approved for use in adult ITP.
These second-line agents represent a new
class of treatment for ITP. TRAs stimulate
megakaryopoiesis, inducing megakaryocyte
proliferation and differentiation with an
increase in platelet count. From phase I–III
trials both drugs are highly effective at raising
platelet counts in healthy volunteers and
patients with chronic ITP [57, 58]. This article
is based on previously conducted studies and
does not involve any new studies of human or
animal subjects performed by any of the
authors.
ROMIPLOSTIM
This molecule is an FC peptide fusion
peptibody. The module consists of a
14-amino-acid peptide dimer covalently linked
to two disulphide-bonded human IgG1 kappa
light chains. This carrier FC protein prolongs the
half-life of the drug. Romiplostim stimulates
megakaryopoiesis after subcutaneous injection.
The rise in platelet count is dose-dependent and
patients start treatment of 1 lg/kg bodyweight
weekly increasing by 1 lg/kg weekly until the
desired platelet count is achieved [58].
The initial phase I double-blind
placebo-controlled trial involved 48 healthy
volunteers [59]. Those receiving romiplostim
by single IV injection at 10 lg/kg showed
elevated platelet counts at over 1000 9 109/l.
The first study in patients with ITP used a dose
of 0.2–10 lg/kg on days 1 and day 15 [52]. Seven
of 12 patients at 3, 6 or 10 lg/kg achieved a
platelet count of greater than 50 9 109/l. The
open dose escalation phase I/II study
investigated the safety and efficacy in 16
patients with platelets less than 30 9 109/l
[60]. Doses between 30 and 500 lg were given
on days 1 and 15. Platelet counts of 50 9 109/l
or greater were seen in all patients. Two parallel
phase III studies were carried out in Europe and
the USA [55]. Twenty-four of 52 patients were
treated with 1 lg/kg or placebo every 7 days
with dose adjustment based on platelet counts.
One hundred twenty-eight patients were
recruited and all of these has severe and
refractory ITP. One-third were taking
concomitant medication. Sixteen of 42 on
romiplostim had a durable response (platelets
greater than 50 9 109/l for at least 6 out of the
last 8 weeks treatment) in the splenectomised
group and in 25 of 41 in the
non-splenectomised arm. Combining both
durable and transient responses 36 out of 41
were seen in the non-splenectomised group and
33 out of 42 in the splenectomised group. There
was no recorded risk of thromboembolism in
the romiplostim arm [61].
The 12-week study of romiplostim versus
placebo was carried out in splenectomised and
non-splenectomised Japanese patients with
chronic severe ITP [62]. The mean increase in
platelet count from baseline was 110 9 109/l in
those receiving romiplostim compared with
2 9 109/l in the placebo arm.
Results are available for up to 5 years
continuous dosing involving 292 adults.
Platelet counts of greater than 50 9 109/l were
recorded at least once by more than 95% of
subjects in the study [63]. Ninety-eight per cent
experienced adverse events during the
follow-up period including headache in 38%,
fatigue in 32%, contusion in 31%, upper
respiratory tract infection in 26%, diarrhoea in
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25% and epistaxis in 25%. Nineteen patients
experienced 25 thromboembolic events (arterial
and venous equally). There was no association
with platelet count and only six of these were
considered to be related to romiplostim.
Neutralising antibodies to romiplostim were
found in twopatients (1%). These antibodieswere
measured when the patients’ platelet counts fell.
Antibodies became undetectable after
romiplostim was stopped and no cross-reactivity
with endogenous TPO was seen.
ELTROMBOPAG
This is a small molecule of 564.6 Da molecular
weight. Eltrombopag is one of the
naphthalenesulfonic acids with a potency
similar to native TPO [64]. Eltrombopag
stimulates megakaryopoiesis in vitro [65]. A
phase I study, similar to that of romiplostim,
showed a dose-dependent rise in platelet counts
[57] and a randomised double-blind
placebo-controlled phase II study confirmed
both its efficacy and safety [53]. The first phase
III study was a 6-week double-blind randomised
controlled trial in chronic severe ITP with
platelets less than 30 9 109/l. Eltrombopag
showed a response rate of 59% compared to
16% with placebo. Common adverse events
where non-serious and transient. Deranged liver
function tests were seen in some patients.
A 6-month study, RAISE, a randomised
controlled double-blind study to evaluate
efficacy, safety and tolerability, was conducted
[66]. Platelets of over 50 9 109/l were seen in
106 (79%) patients in the eltrombopag arm
compared to 17 (28%) in the placebo arm.
Concomitant medication was reduced by 59%
in the eltrombopag arm compared to 32% in
the placebo arm. Rescue medications were
reduced with only 18% in the eltrombopag
arm requiring rescue medication compared to
40% requiring rescue medication in the placebo
arm. The risk of bleeding was 76% lower in the
eltrombopag arm. Thromboembolic events
were reported in 2% of patients (0 in the
placebo arm). There was a 7% increase in
transaminases in the eltrombopag arm
compared to only 3% in the placebo arm.
EXTEND was an open-label study that
recruited patients who had been enrolled in
previous eltrombopag studies [67]. A total of
299 patients were treated with eltrombopag for
up to 3 years. No new safety issues were
reported. Most patients achieved a platelet
count response at least once during this period
(80% of splenectomised and 88% of
non-splenectomised). Responses were
maintained for a median of 73/104 cumulative
weeks for the non-splenectomised arm.
TRAs MAY INDUCE SUSTAINED
REMISSIONS
Romiplostim and eltrombopag are licensed for
use in adults with chronic ITP. The drugs
stimulate megakaryocyte proliferation and
platelet production. The expectation when
using these agents is that the platelet count
will rise when taking the TRA but will drop to
baseline levels when the drug is stopped. These
drugs were not licensed with any curative
intent. However, published reports show that
a proportion of patients may achieve a
sustained response to the TRAs even after the
drugs have been stopped.
One study of 54 adults treated with at least
one TRA over a 5-year period found that 20 of
28 patients (28.5%) who achieved a complete
response had a sustained response after
stopping the TRA. The median follow-up was
13.5 months. No factors predictive of sustained
response were identified [68]. In another study,
46 patients with primary ITP were treated using
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a TRA. Eleven of 46 patients (24%) were able to
stop the TRA (7 romiplostim, 4 eltrombopag)
and sustained their platelet counts. Again no
predictive factors of sustained response were
found [69]. Ghadaki and colleagues reported
sustained responses in 9 of 31 patients (29%)
treated with a TRA. Four of the nine patients
subsequently relapsed [70]. Provan et al.
reported sustained responses after
discontinuing romiplostim in 5 of 21 patients
(24%). All patients had received multiple prior
therapies. The median duration of the
romiplostim administration was 26 months
(range 7–60 months). As with previous studies
no predictive factors were identified [71]. A
more recent phase 2, single-arm study looked at
75 patients less than 6 months from
presentation who had failed first-line
treatment and had a continuing platelet count
of less than 30 treated with romiplostim [72].
Responses occurred rapidly in more than 90%
and long-term remission occurred in 32%,
which were sustained for more than 6 months
off all treatment. Again no predictive clinical
features could be identified but the studies
confirm that a significant proportion of
patients can safely stop treatment.
A large series of patients (260) treated with
eltrombopag was evaluated by Gonzalez-Lopez
and colleagues [73]. Out of 49 evaluable
patients, 26 (53%) had a sustained response
after stopping eltrombopag with a median
follow-up of 9 months.
From the published data, therefore, it would
appear that 25–30% of patients receiving a TRA
may expect a sustained response on stopping
the drug. The mechanism for these sustained
responses is not clear. Some of these patients
may have had a spontaneous remission but the
patients in all reported studies had received
several prior treatments and had severe
thrombocytopenia for some considerable time.
Spontaneous remission is therefore unlikely.
The TRAs may have an effect on regulatory T
cells (Tregs). These cells naturally suppress
autoimmune disease [74]. From studies of
rituximab used for the treatment of ITP it
would appear that those patients who respond
to rituximab normalise their Tregs; those that
fail to respond to rituximab do not [75]. The use
of the TRAs may have an effect on the Treg
compartment returning Tregs to normal
number and function, thereby restoring
tolerance. However, this has not been
confirmed to date.
Alternatively tolerance may be induced by
increasing megakaryocyte and platelet mass
through the use of TRAs in much the same
way as giving large doses of factor VIII is used to
induce tolerance in acquired haemophilia.
Clearly more basic science is required in
order to determine the underlying mechanism
leading to sustained responses in these chronic
ITP patients.
CONCLUSION
Over the past decade, and certainly since the
publication of the International Consensus
Report [3] and revised American Society of
Hematology guidelines [76], there has been a
major change in the way ITP is managed.
Patients are now treated based on symptoms
and signs rather than using an arbitrary platelet
threshold. Because of this fewer patients are
receiving medical therapies for ITP. Previously
used treatments for ITP had low efficacy and
considerable side effects for many patients.
With the introduction of the TRAs the
management of ITP has been transformed.
These new agents have very high efficacy and
few side effects. The TRAs are effective in even
the most refractory patients who can expect to
achieve a platelet count that is safe and in many
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cases a normal platelet count. It should be
noted, however, that the TRAs should not be
used to normalise the platelet count but rather
achieve a safe platelet count. After being on a
TRA for some time, perhaps a year or 2, around
25–30% of patients may achieve a sustained
remission with safe or normal platelet counts
off therapy. The underlying mechanisms
inducing these sustained responses remain to
be elucidated.
There are also on-going trials of other
treatments with new classes of drugs such as
Syk inhibitors (fostamatinib), antibody
therapies such as anti-CD40 ligand
(anti-CD154), GMA161 (anti-CD16),
dacluzumab and alemtuzumab, avatrombopag
[77], and others. Once these have been
approved for use patients with ITP should
expect to have a much higher quality of life
because of the low incidence of toxicities and
high efficacy of these newer agents with fewer
patients receiving the older types of
immunosuppressive therapy.
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